{"title": "Nuevos tratamientos para la degeneraci\u00f3n macular relacionada con la edad", "author": "Daniel Porter", "url": "https://www.aao.org/salud-ocular/consejos/nuevos-tratamientos-prometedores-para-la-dmre", "hostname": "aao.org", "description": "No existen tratamientos para la forma m\u00e1s com\u00fan de degeneraci\u00f3n macular relacionada con la edad (DMRE). Pero, seg\u00fan los expertos, eso puede cambiar pronto. Estos son algunos de los tratamientos m\u00e1s in", "sitename": "American Academy of Ophthalmology", "date": "2020-11-15", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Durante m\u00e1s de una d\u00e9cada, los oftalm\u00f3logos han tratado la\n[degeneraci\u00f3n macular relacionada con la edad (DMRE)](/salud-ocular/enfermedades/dmre-degeneracion-macular-relacionada-edad) con [inyecciones oculares](/salud-ocular/medicamentos/tratamientos-anti-vegf) administradas cada mes o cada dos meses, y la DMAE seca con [vitaminas antioxidantes](/salud-ocular/enfermedades/vitaminas-para-dmre). Estos tratamientos fueron innovadores cuando se introdujeron, ofreciendo por primera vez la esperanza de que esta enfermedad que amenaza la visi\u00f3n podr\u00eda retardarse y, en algunos casos, detenerse o incluso revertirse. Esta revoluci\u00f3n est\u00e1 experimentando una evoluci\u00f3n interesante. Entonces \u00bfQu\u00e9 depara la pr\u00f3xima d\u00e9cada para los 11 millones de norteamericanos con DMRE?\nEn resumen, la investigaci\u00f3n m\u00e1s reciente es variada, vibrante y sugiere un futuro en el que los oftalm\u00f3logos tendr\u00e1n opciones m\u00e1s efectivas para proteger a las personas de quedar legalmente ciegas a causa de la DMRE. Aqu\u00ed hay un resumen de los tratamientos para la DMRE m\u00e1s prometedores en el panorama.\nNuevos tratamientos para la DMRE h\u00fameda\nLa visi\u00f3n se pierde m\u00e1s r\u00e1pido con la DMRE h\u00fameda que con la DMRE seca.\nLa DMRE h\u00fameda se desarrolla cuando\n[crecen nuevos vasos sangu\u00edneos anormales debajo de la retina](/salud-ocular/enfermedades/dmre-degeneracion-macular-relacionada-edad). Estos vasos pueden filtrar sangre u otros fluidos, causando [cicatrices en la m\u00e1cula](/salud-ocular/enfermedades/fotograf%c3%adas-y-video-de-la-dmre-c%c3%b3mo-se-ve-la-degen). Hace aproximadamente 15 a\u00f1os, los cient\u00edficos crearon medicamentos que interfieren con este proceso al bloquear una prote\u00edna llamada factor de crecimiento endotelial vascular (VEGF, por su sigla en ingl\u00e9s). Antes de la creaci\u00f3n de estos llamados medicamentos anti-VEGF, era casi seguro que las personas con DMRE h\u00fameda desarrollar\u00edan una p\u00e9rdida severa de la visi\u00f3n o ceguera.\nSeg\u00fan el Dr. Jayanth Sridhar, profesor asistente de oftalmolog\u00eda cl\u00ednica en la Facultad de Medicina Miller de la Universidad de Miami, \u201cHace veinte a\u00f1os, la DMRE h\u00fameda era una sentencia de muerte para la visi\u00f3n\u201d.\nLuego, en 2005, los\n[medicamentos anti-VEGF](/salud-ocular/medicamentos/tratamientos-anti-vegf) abrieron camino al salvar la visi\u00f3n de los pacientes con DMRE h\u00fameda. Estos medicamentos estabilizan o mejoran la visi\u00f3n en la gran mayor\u00eda de los pacientes. Pero deben inyectarse en el ojo de forma regular.\n\"Hoy en d\u00eda, est\u00e1n surgiendo terapias m\u00e1s duraderas y se est\u00e1n preparando tratamientos que incluso pueden curar la enfermedad. Hay muchas esperanzas para las personas con DMRE\", sostiene el Dr. Sridhar.\nSi bien los ensayos cl\u00ednicos muestran que las inyecciones anti-VEGF han permitido que m\u00e1s del 90% de los pacientes conserven su visi\u00f3n, en el mundo real el porcentaje se acerca al 50%. Esto se debe a que a los pacientes no reciben el tratamiento con la regularidad con la que deber\u00edan. El problema es que la mayor\u00eda de las personas necesitan una inyecci\u00f3n cada cuatro a ocho semanas para mantener su visi\u00f3n. Este puede ser dif\u00edcil de hacer para muchos pacientes de edad avanzada que luchan con otras enfermedades y dependen de otras personas para llevarlos a sus visitas de oftalmolog\u00eda.\nAlgunas de las investigaciones m\u00e1s interesantes de la actualidad, buscan mejores alternativas a las inyecciones frecuentes. No se trata solo de conveniencia; la esperanza es que un tratamiento m\u00e1s consistente tambi\u00e9n ayude a las personas a conservar m\u00e1s su visi\u00f3n.\nTerapia gen\u00e9tica para la DMRE h\u00fameda\nLa terapia gen\u00e9tica es una alternativa prometedora a las inyecciones oculares continuas de medicamentos como\n[Eyelea, Lucentis y Avastin](/salud-ocular/noticias/avastin-eylea-y-lucentis-cual-es-la-diferencia). El objetivo de la terapia gen\u00e9tica es proporcionar un tratamiento \"\u00fanico\" ayudando al ojo a producir su propio medicamento anti-VEGF. Se est\u00e1n investigando dos m\u00e9todos diferentes: en el primero, se inyecta el ojo con terapia gen\u00e9tica debajo de la retina en un procedimiento quir\u00fargico; y en el segundo se inyecta el ojo al igual que como se realiza un tratamiento anti-VEGF de rutina en el consultorio del m\u00e9dico.\nSe est\u00e1n investigando cuatro medicamentos candidatos diferentes para la DMRE h\u00fameda y uno para la DMRE seca. A pesar de lo prometedora que pueda ser la terapia gen\u00e9tica, queda por comprobarse la eficacia a largo plazo. Entre los desaf\u00edos a los que se enfrenta, probablemente el m\u00e1s significativo sea el alto costo de dicho tratamiento.\nNuevos m\u00e9todos para administrar medicamentos en el ojo.\nUn enfoque prometedor que podr\u00eda estar disponible pronto, es un dispositivo recargable de medicamento. El\n[sistema de administraci\u00f3n de puertos (SAP)](https://www.aao.org/newsroom/news-releases/detail/easier-potentially-more-effective-treatment-blindi) es un peque\u00f1o dispositivo recargable que almacena el medicamento anti-VEGF Lucentis. No m\u00e1s grande que un grano de arroz, el puerto se implanta en la pared del ojo, justo debajo del p\u00e1rpado, durante un procedimiento quir\u00fargico. El dispositivo libera medicamento continuamente en la parte posterior del ojo a lo largo del tiempo. En lugar de una inyecci\u00f3n cada seis a ocho semanas, los pacientes pueden recargar este dispositivo una o dos veces al a\u00f1o en el consultorio del m\u00e9dico. El dispositivo se puede rellenar con una aguja especial. Los \u00faltimos estudios muestran que muchas personas tratadas de esta manera, pudieron pasar 15 meses entre un tratamiento y otro.\nMedicamentos que tratan m\u00faltiples causas de la DMRE h\u00fameda\nLos tratamientos anti-VEGF son efectivos porque apuntan a un factor clave que contribuye a la DMRE h\u00fameda: VEGF. Pero \u00bfY si un medicamento pudiera tratar dos causas subyacentes de la DMRE? Esa es la idea detr\u00e1s del medicamento\n[faricimab](https://eyewire.news/articles/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/). Se dirige tanto al VEGF como a la prote\u00edna angiopoyetina-2. Se inyecta en el ojo como un tratamiento anti-VEGF est\u00e1ndar, pero dura mucho m\u00e1s. La \u00faltima investigaci\u00f3n muestra que los pacientes pueden pasar hasta cuatro meses entre un tratamiento y otro. Sin embargo, estos datos son tan nuevos que a\u00fan no se han publicado en una revista reconocida por expertos.\nTambi\u00e9n puede ser posible combinar dos medicamentos y dar un golpe doble a la DMRE h\u00fameda. Estos \u201cgolpes\u201d podr\u00edan mejorar la visi\u00f3n y hacer que las inyecciones duren m\u00e1s. Cosopt (dorzolamida-timolol), unas gotas oftalmol\u00f3gicas que ya se usan para tratar el glaucoma, se est\u00e1n probando en combinaci\u00f3n con inyecciones anti-VEGF. Los estudios han demostrado que el d\u00fao puede reducir la acumulaci\u00f3n de l\u00edquido retiniano y durar m\u00e1s que una inyecci\u00f3n anti-VEGF sola. El\n[OPT-302 de Opthea](https://www.globenewswire.com/news-release/2019/09/06/1912077/0/en/Opthea-Presents-Positive-Data-from-OPT-302-Phase-2b-Wet-AMD-Trial-at-EURETINA-Congress.html) se dirige a una prote\u00edna que contribuye a la DMRE h\u00fameda: la angiopoyetina II. La combinaci\u00f3n de Opthea con una inyecci\u00f3n anti-VEGF puede funcionar mejor y durar m\u00e1s que las inyecciones anti-VEGF actuales.\nLas inyecciones anti-VEGF de mayor duraci\u00f3n\nLos fabricantes de medicamentos est\u00e1n creando nuevos tratamientos anti-VEGF que no necesitan inyectarse en el ojo con tanta frecuencia como Eyelea, Lucentis o Avastin.\nEl nuevo medicamento de Novartis,\n[Beovu](https://www.medscape.com/viewarticle/919605), est\u00e1 ahora aprobado para su uso en los Estados Unidos. Aproximadamente uno de cada tres pacientes que usan Beovu, y pueden pasar hasta tres meses sin necesitar otra inyecci\u00f3n. Beovu puede hacer un mejor trabajo que otros medicamentos para secar el l\u00edquido de la retina, en pacientes con DMRE h\u00fameda.\nEl\n[Abicipar de Allergan](https://eyewire.news/articles/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/) todav\u00eda se encuentra en ensayos cl\u00ednicos de fase 3 y a\u00fan no ha obtenido la aprobaci\u00f3n de la FDA. Los estudios sugieren que este medicamento permite a los pacientes pasar tres meses entre una inyecci\u00f3n y otra. Este medicamento tambi\u00e9n se est\u00e1 evaluando para el tratamiento del edema macular.\nOtro medicamento inyectable \u2014\n[Sunitinib de Graybug Vision](https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Ba9878186-08f0-440f-8cda-5711331892f1%7D/novel-anti-vegf-for-wet-amd-meets-safety-tolerability-endpoint) \u2014 tiene el potencial de brindar a los pacientes 6 meses de durabilidad entre un tratamiento y otro. Sunitinab reci\u00e9n est\u00e1 entrando en ensayos cl\u00ednicos de fase 2B. Es posible que a\u00fan falten de 3 a 5 a\u00f1os para que est\u00e9 disponible.\nNuevos tratamientos para la DMRE seca\nAproximadamente 8 de cada 10 personas con DMRE tienen la forma seca. La DMRE seca ocurre cuando partes de la m\u00e1cula se adelgazan con la edad y crecen peque\u00f1os grupos de prote\u00edna llamados\n[drusen](/salud-ocular/enfermedades/drusas). Usted [pierde lentamente la visi\u00f3n central](/salud-ocular/enfermedades/dmre-simulador). Dependiendo de la gravedad, la DMRE seca se considera en etapa temprana, intermedia o tard\u00eda.\nPara las personas con enfermedad intermedia, una formulaci\u00f3n de\n[vitaminas antioxidantes](/salud-ocular/enfermedades/vitaminas-para-dmre) llamada f\u00f3rmula AREDS2, puede ayudar a reducir el riesgo de p\u00e9rdida de la visi\u00f3n. Pero para las personas con DMRE en etapa tard\u00eda, tambi\u00e9n llamada [atrofia geogr\u00e1fica](https://www.aao.org/eye-health/ask-ophthalmologist-q/with-dry-amd-is-there-risk-geographic-atrophy) (AG), no hay ning\u00fan tratamiento disponible. Sin embargo, hay varios ensayos cl\u00ednicos prometedores en curso.\nTratamientos para la DMRE seca que se dirigen al sistema inmunol\u00f3gico\nUna parte del sistema inmunol\u00f3gico llamada \"cascada del complemento\" ha sido identificada durante mucho tiempo como la culpable de la DMRE. Dos nuevos medicamentos que se dirigen a la cascada del complemento y evitan que ataque la retina, han avanzado recientemente a ensayos cl\u00ednicos en etapa tard\u00eda. Uno (pegcetacoplan,\n[APL-2](https://eyesight.org/2019/06/08/promising-update-on-apl-2-for-dry-amd/)) se dirige a una prote\u00edna del complemento llamada C3, el otro candidato a medicamento ( [Zimura](https://lowvision.preventblindness.org/2019/10/29/zimura-for-dry-amd-continues-to-show-positive-results-in-trials/), avacincaptad pegol) se dirige a una prote\u00edna diferente en la cascada, llamada C5. Al igual que los tratamientos disponibles en la actualidad para la DMRE h\u00fameda, estos medicamentos se inyectan directamente en el ojo del paciente. Ya se ha demostrado su seguridad en las personas, y [ahora los investigadores est\u00e1n estudiando](https://www.apellis.com/our-science/) si pueden mejorar sustancialmente la visi\u00f3n. Los resultados se esperan para dentro de un a\u00f1o.\nReemplazo de las c\u00e9lulas de la visi\u00f3n en personas con DMRE seca\nOtro concepto que se est\u00e1 investigando, es la posibilidad de reemplazar algunas c\u00e9lulas que comienzan a morir con la DMRE seca en etapa tard\u00eda. Las\n[c\u00e9lulas madre](/salud-ocular/consejos/terapia-de-ceulas-madre-para-enfermedad-ocular) pueden reemplazar las c\u00e9lulas de la retina que son destruidas por esta enfermedad. Los m\u00e9dicos est\u00e1n planeando formas de trasplantar estas c\u00e9lulas madre en el ojo. Una estrategia consiste en colocar las c\u00e9lulas madre en capas delgadas. Otra t\u00e1ctica es poner las c\u00e9lulas en una suspensi\u00f3n l\u00edquida que se puede inyectar debajo de la retina. Las c\u00e9lulas madre se han probado en peque\u00f1os ensayos cl\u00ednicos y no tienen efectos secundarios inesperados. Es posible que se necesiten entre 10 y 15 a\u00f1os para que estas terapias se ajusten y se demuestre su eficacia en los seres humanos.", "language": null, "image": "/image.axd?id=5fec0da1-41e6-4ff8-9d27-9f5f43607375&t=637426977454570000", "pagetype": "article", "links": ["#contentZone", "#menu", "/dashboard", "/my-education", "https://secure.aao.org/aao/find-ophthalmologist", "/", "/ophthalmologists", "/meetings", "/annual-meeting", "/annual-meeting/meeting-information", "/annual-meeting/past-and-future-meetings", "/annual-meeting/mobile-meeting-guide", "/annual-meeting/contact", "/annual-meeting/news", "/annual-meeting/health-safety", "/annual-meeting/policies-and-disclaimers", "/program", "/annual-meeting/highlights", "/annual-meeting/subspecialty-day", "/annual-meeting/virtual-meeting", "/annual-meeting/program-committees", "/annual-meeting/cme", "/annual-meeting/meeting-archives", "/annual-meeting/exhibition", "/annual-meeting/registration", "/annual-meeting/hotel-reservation", "/annual-meeting/hotel-reservation", "/annual-meeting/san-francisco", "/annual-meeting/international-attendees", "/annual-meeting/hotel-meeting-space", "/annual-meeting/presenter", "/annual-meeting/presenter/overview", "/annual-meeting/presenter/abstract-selection-process", "/annual-meeting/presenter/submission-policies", "/annual-meeting/presenter/subject-classification-topics", "/annual-meeting/presenter/instruction-courses-and-skills-transfer-labs", "/annual-meeting/presenter/paper-posters", "/annual-meeting/presenter/videos", "/annual-meeting/presenter/grand-round", "/annual-meeting/presenter/guidelines", "/annual-meeting/presenter/faculty-development", "/annual-meeting/exhibitor", "/annual-meeting/exhibitor/general-information", "/annual-meeting/exhibitor/portal", "/annual-meeting/exhibitor/new-exhibiting-companies", "/annual-meeting/exhibitor/resources", "/annual-meeting/exhibitor/international-exhibitors", "/annual-meeting/exhibitor/promotional-opportunities", "/annual-meeting/exhibitor/hotel", "/mid-year-forum", "/mid-year-forum/registration-travel", "/mid-year-forum/congressional-advocacy-day", "/mid-year-forum/advocacy-ambassador-program", "/mid-year-forum/program", "/mid-year-forum/schedule", "/mid-year-forum/sponsored-attendee-reimbursement", "/mid-year-forum/news", "/practice-management/coding/codequest", "/practice-management/coding/codequest-instructors", "/practice-management/coding/codequest/cme", "/eyecelerator", "/clinical-education", "/education-browse", "/education-browse", "/education-course", "/education-case", "/education-learning-plan", "/interactive", "/focalpoints", "/wills-eye-manual", "/disease-reviews", "/clinical-webinars", "/education-diagnose-this", "/self-assessments", "/glaucoma-education-center", "/pediatric-ophthalmology-education-center", "/global-ophthalmology-guide", "/laser-surgery-education-center", "/redmond-ethics-center", "/myopia-resources", "/thyroid-eye-disease", "/journals", "/guidelines-browse", "/guidelines-browse", "/education/covid-19", "https://www.aao.org/education/pseudomonas-outbreak", "/preferred-practice-patterns", "/clinical-statements", "/compendium-guidelines", "/complementary-therapy-assessments", "/medical-information-technology-guidelines", "/ophthalmic-technology-assessments", "/patient-safety-statements", "/choosing-wisely", "/low-vision-and-vision-rehab", "/eye-care-for-older-adults", "/eye-disease-statistics", "/about-hoskins-center", "/education/browse-multimedia?filter=Video&sub=ONE.ContentTypes.ONEVideo", "/education/browse-multimedia?filter=Video&sub=ONE.ContentTypes.ONEVideo", "/1-minute-videos", "/presentations-and-lectures", "/master-class-videos", "/clinical-and-surgical-videos", "/multimedia-basic-skills", "/interviews", "/multimedia-images", "/submit-an-image", "/submit-a-video", "/podcasts", "https://www.aao.org/education/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio", "/education/audio/experts-insight", "/education/audio/ophthalmology-journal", "/browse-news", "/browse-news", "/editorschoice", "/headlines", "/currentinsight", "/cme-central", "/cme-central", "/certification", "/claim-cme-credit-and-view-transcript", "/cme-planning-resources", "/complete-your-financial-disclosure", "/leo-continuing-education-recognition-award", "/safe-er-la-opioid-prescribing", "/check-your-industry-payment-records", "/residents", "/residents", "/browse-all-resident-content", "/resident-blog-posts", "/resident-courses", "/resident-flashcards", "/interactive-cases-and-simulations", "/resident-videos", "/resident-webinars", "/cataract-master", "/diversity-and-inclusion-education", "/news-and-advice-from-yo-info", "/okap-and-board-exam-resources", "/okap-exam", "/board-prep-resources", "/okap-study-presentations", "/flashcards", "/pediatric-ophthalmology-education-center-residents", "/pgy-1-and-pgy-2-resources", "/resident-knowledge-exchange", "/simulation-in-resident-education", "https://ophthjobs.aao.org", "/membership-transfer", "/membership/join", "/membership/renew", "/membership/current-member", "/membership/volunteer", "/membership/physician-wellness", "/member-directory", "/membership/obituaries", "/membership/aaoe", "/advocacy", "/advocacy/eye-on-advocacy", "/advocacy/action", "/advocacy/action/give", "/advocacy/action/how-to-get-involved", "/advocacy/action/congressional-advocacy", "/advocacy/action/support-oppose-bills", "/advocacy/action/look-up-bill", "/action/contact-legislator", "/advocacy/i-am-an-advocate", "/advocacy/action/local", "/advocacy/action/vv", "/advocacy/action/best-practices", "/get-involved/social-media-toolkit", "/get-involved/letter-to-editor", "/get-involved/town-hall-guide", "/get-involved/guide-to-engaging-with-new-lawmakers", "/get-involved/resources", "/get-involved/attending-a-political-fundraiser", "/advocacy/ophthpac", "/advocacy/ophthpac/about", "/advocacy/ophthpac/contribute", "/advocacy/ophthpac/blog", "/advocacy/surgical-scope-fund", "/advocacy/surgical-scope-fund/contribute", "/advocacy/surgical-scope-fund/blog", "/eyenet-magazine", "/eyenet", "/eyenet/archives", "/eyenet/subscribe", "/eyenet/advertise", "/eyenet/write-for-us", "/eyenet/corporate-events", "/eyenet/contact", "/eyenet/mips-manual-2022", "/focalpoints", "https://secure.aao.org/aao/aao-redirect?redirectid=100&article=http%3a%2f%2fwww.aaojournal.org%2f", "https://secure.aao.org/aao/aao-redirect?redirectid=100&article=https%3a%2f%2Fwww.ophthalmologyglaucoma.org", "https://secure.aao.org/aao/aao-redirect?redirectid=100&article=https%3a%2f%2Fwww.ophthalmologyretina.org", "https://www.ophthalmologyscience.org/", "https://www.aao.org/young-ophthalmologists/yo-info", "https://www.aao.org/senior-ophthalmologists/scope", "/cataract-anterior-segment", "/comprehensive-ophthalmology", "/cornea-external-disease", "/glaucoma", "/neuro-ophthalmology-orbit", "/ocular-pathology-oncology", "/oculoplastics-orbit", "/pediatric-ophthalmology-strabismus", "/refractive-management-intervention", "/retina-vitreous", "/uveitis", "/iris-registry", "/iris-registry/about", "/iris-registry/ways-to-use", "/iris-registry/userguide", "/iris-registry/medicare-reporting", "/iris-registry/maintenance-of-certification", "/iris-registry/web-portal-reporting", "/iris-registry/sign-up", "/iris-registry/application-process", "/iris-registry/why-participate", "/iris-registry/getting-started-system-integration", "/sign-up/what-practices-are-saying-about-the-registry", "/iris-registry/requirements", "/iris-registry/ehr-systems", "/iris-registry/data-technical-needs", "/iris-registry/research", "/iris-registry/portal", "/iris-registry/news", "/medicare", "/medicare-information", "/diversity-equity-and-inclusion", "/practice-management", "/practice-management/managing-your-practice", "/practice-management/managing-your-practice/managing-practice-index", "/practice-management/resources/coronavirus-resources", "/practice-management/resources/reopening-recovery", "/practice-management/practice-forms-library", "/practice-management/articles-list", "/practice-management/listserv-overview", "/practice-management/resources/videos", "https://ophthjobs.aao.org/", "/practice-management/analytics", "https://store.aao.org/consultation-services", "/practice-management/consultant-directory", "/practice-management/coding", "/practice-management/coding/coding-index", "/practice-management/coding/codequest", "/practice-management/coding-news", "/practice-management/coding/updates-resources", "/practice-management/coding/injectable-drugs", "/practice-management/coding/em-codes", "/practice-management/coding/icd-10-cm", "/practice-management/coding/ocs-specialist-exam", "/practice-management/coding/retina", "/practice-management/coding/savvy-coder", "/practice-management/annual-meeting", "/practice-management/annual-meeting-courses/master-classes", "/practice-management/annual-meeting-courses/coding-sessions", "/submit-an-instruction-course", "/codequest-courses", "/mid-year-forum/overview", "/practice-management/resources/videos", "/upcoming-webinars", "/iris-registry", "/medicare/mips", "/medicare", "/medicare/mips", "/medicare/quality-overview", "/medicare/promoting-interoperability", "/medicare/improvement-activities-overview", "/medicare/cost", "/medicare/avoid-a-penalty", "/medicare/resources", "/practice-management/regulatory/medicare-participation-options", "/practice-management/regulatory/medicare-advantage-plans", "/practice-management/regulatory/medicare-card-2019", "/practice-management/regulatory/pecos", "/practice-management/regulatory/regulatory-compliance", "/practice-management/regulatory/hipaa-resources", "/practice-management/regulatory/regulatory-compliance#oig", "/practice-management/regulatory/audits", "/practice-management/regulatory/regulatory-compliance#osha", "/membership/aaoe", "/membership/join-aaoe", "/membership/benefits/aaoe", "https://secure.aao.org/aao/aao-pay-dues#/", "/practice-management/about-aaoe", "/practice-management/about/board", "/practice-management/about/content-committee", "/practice-management/get-involved", "/clinical-teams", "/clinical-teams/aaop-membership/join-aaop", "/clinical-teams/education", "/clinical-teams/build-your-career", "/clinical-teams/annual-meeting", "/clinical-teams/about-aaop", "/eye-health", "/eye-health/a-z", "/eye-health/symptoms-list", "/eye-health/glasses-contacts-list", "/eye-health/tips-prevention-list", "/eye-health/news-list", "/eye-health/ask-ophthalmologist", "/eye-health/patient-stories", "/no-cost-eye-exams", "/eye-health/espanol", "/salud-ocular/a-z", "/salud-ocular/sintomas-lista", "/salud-ocular/anteojos-lentes-de-contacto-lista", "/salud-ocular/consejos-lista", "/salud-ocular/noticias-lista", "/salud-ocular/relatos-de-pacientes", "/salud-ocular/ex-menes-de-la-vista-sin-costo", "/salud-ocular/english", "/annual-meeting", "/annual-meeting/meeting-information", "/annual-meeting/past-and-future-meetings", "/annual-meeting/mobile-meeting-guide", "/annual-meeting/contact", "/annual-meeting/news", "/annual-meeting/health-safety", "/annual-meeting/policies-and-disclaimers", "/program", "/annual-meeting/highlights", "/annual-meeting/subspecialty-day", "/annual-meeting/virtual-meeting", "/annual-meeting/program-committees", "/annual-meeting/cme", "/annual-meeting/meeting-archives", "/annual-meeting/exhibition", "/annual-meeting/registration", "/annual-meeting/hotel-reservation", "/annual-meeting/hotel-reservation", "/annual-meeting/san-francisco", "/annual-meeting/international-attendees", "/annual-meeting/hotel-meeting-space", "/annual-meeting/presenter", "/annual-meeting/presenter/overview", "/annual-meeting/presenter/abstract-selection-process", "/annual-meeting/presenter/submission-policies", "/annual-meeting/presenter/subject-classification-topics", "/annual-meeting/presenter/instruction-courses-and-skills-transfer-labs", "/annual-meeting/presenter/paper-posters", "/annual-meeting/presenter/videos", "/annual-meeting/presenter/grand-round", "/annual-meeting/presenter/guidelines", "/annual-meeting/presenter/faculty-development", "/annual-meeting/exhibitor", "/annual-meeting/exhibitor/general-information", "/annual-meeting/exhibitor/portal", "/annual-meeting/exhibitor/new-exhibiting-companies", "/annual-meeting/exhibitor/resources", "/annual-meeting/exhibitor/international-exhibitors", "/annual-meeting/exhibitor/promotional-opportunities", "/annual-meeting/exhibitor/hotel", "/about/who-we-are/overview", "/about/who-we-are/overview", "/about/what-we-do", "/eye-health/tips-prevention/what-is-ophthalmologist", "/about/eye-care-team", "/about/ethics", "/about/history", "/museum-of-vision", "/about/who-we-are/values", "/about/governance/overview", "/about/governance/council", "https://secure.aao.org/aao/Rosters/Board-Of-Trustees", "/about/governance/committees", "/about/governance/past-presidents", "https://secure.aao.org/aao/Rosters/Committee-of-secretaries", "/about/governance/elections", "/about/governance/academy-blog", "/governance/staff-leadership", "/about/leadership-development/overview", "/about/awards/program", "/about/awards/laureate", "/about/awards/advocate", "/about/awards/humanitarian", "/about/awards/blindness-prevention", "/about/awards/distinguished-service", "/about/awards/guests-of-honor", "/about/awards/secretariat", "/about/awards/straatsma", "/about/awards/achievement", "/about/awards/artemis", "/about/awards/energEYES", "/about/awards/international-education", "/about/awards/international-scholar", "/about/awards/commitment-to-advocacy", "/about/awards/visionary-society-award", "/about/financial-relationships", "/about/policies", "/about/related-organizations/overview", "https://secure.aao.org/aao/Rosters/Subspecialty-and-Special-Interest-Societies", "https://secure.aao.org/aao/Rosters/State-societies", "/about/related-organizations/overview", "/about/related-organizations/state-society-meetings", "/about/related-organizations/society-resources", "/about/year-in-review", "/about/2022-year-in-review", "/foundation", "/foundation/about", "/foundation/2022-annual-report", "/foundation/annual-report", "/foundation/news-from-the-chair", "/foundation/staff", "/foundation/our-impact", "/foundation/partners-for-sight", "/foundation/donor", "/foundation/global-ophthalmic-community", "/foundation/corporate-support/sponsorships", "/foundation/patients-and-the-public", "/foundation/giving-options", "/foundation/our-supporters", "https://aao.planmylegacy.org/", "/foundation/ophthalmic-business-council", "/foundation/parke-center-campaign", "/foundation/parke-center-campaign", "/foundation/museum-campaign", "/foundation/gala-overview", "/foundation/orbital-why-attend", "/foundation/gala-support-opportunities", "/foundation/orbital-gala-sponsors", "https://secure.aao.org/aao/faao", "/foundation/museum-campaign", "/foundation/museum-donor-honor-roll", "/museum-of-the-eye", "/visit-museum", "/museum-galleries", "/special-exhibitions", "/museum-events", "/museum/previous-events", "/museum-research-resources", "/museum-search", "/previous-exhibits", "/oral-histories", "/museum-biographies", "/museum-volunteer", "/museum-mailing", "/museum/donate", "/about-the-museum", "/museum-blog", "/young-ophthalmologists", "/young-ophthalmologists/yo-info", "/young-ophthalmologists/learn-to-code", "/young-ophthalmologists/grow-in-leadership", "/young-ophthalmologists/practice-management-yos", "https://ophthjobs.aao.org/", "/senior-ophthalmologists", "/senior-ophthalmologists/scope", "/senior-ophthalmologists/practice-transitions", "/international", "/international/programs", "/international/awards", "/international/outreach", "/residents", "/medical-students", "https://store.aao.org", "/", "/about/who-we-are/overview", "/academy-forum", "/advocacy-overview", "/annual-meeting", "/clinical-education", "/eyecare-america", "/eyenet", "/eye-health", "/salud-ocular", "/foundation", "/membership", "/museum-of-the-eye", "/practice-management", "/senior-ophthalmologists", "/young-ophthalmologists", "/international", "/iris-registry", "/test-page", "/clinical-team", "https://secure.aao.org/aao/Login?returnUrl=https%3a%2f%2fwww.aao.org%2fsalud-ocular%2fconsejos%2fnuevos-tratamientos-prometedores-para-la-dmre", "https://secure.aao.org/aao/CreateAccount?TabId=191?ReturnUrl=%2fsalud-ocular%2fconsejos%2fnuevos-tratamientos-prometedores-para-la-dmre", "https://secure.aao.org/aao/find-ophthalmologist", "javascript:void(0);", "/ophthalmologists", "/practice-management", "/clinical-teams", "/public-patients", "/about", "/foundation", "/museum-of-the-eye", "/salud-ocular/a-z", "/salud-ocular/sintomas-lista", "/salud-ocular/anteojos-lentes-de-contacto-lista", "/salud-ocular/consejos-lista", "/salud-ocular/noticias-lista", "/salud-ocular/relatos-de-pacientes", "/salud-ocular/ex-menes-de-la-vista-sin-costo", "/salud-ocular/english", "/salud-ocular-nav", "/salud-ocular/consejos-lista", "javascript:void(0)", null, "/eye-health/tips-prevention/promising-new-treatments-amd", "https://www.linkedin.com/in/reena-mukamal-2736a05/", "/biography/9b073c1a-85ee-46c9-beef-63ca3fe59d9d", "/biography/5d94d994-6d85-44c7-8be0-7f0634325650", "/biography/8ea5edf5-1544-4f2e-91af-bb57f1da7a15", "/salud-ocular/enfermedades/dmre-degeneracion-macular-relacionada-edad", "/salud-ocular/medicamentos/tratamientos-anti-vegf", "/salud-ocular/enfermedades/vitaminas-para-dmre", "/salud-ocular/enfermedades/dmre-degeneracion-macular-relacionada-edad", "/salud-ocular/enfermedades/fotograf%c3%adas-y-video-de-la-dmre-c%c3%b3mo-se-ve-la-degen", "/salud-ocular/medicamentos/tratamientos-anti-vegf", "/salud-ocular/noticias/avastin-eylea-y-lucentis-cual-es-la-diferencia", "https://www.aao.org/newsroom/news-releases/detail/easier-potentially-more-effective-treatment-blindi", "https://eyewire.news/articles/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/", "https://www.globenewswire.com/news-release/2019/09/06/1912077/0/en/Opthea-Presents-Positive-Data-from-OPT-302-Phase-2b-Wet-AMD-Trial-at-EURETINA-Congress.html", "https://www.medscape.com/viewarticle/919605", "https://eyewire.news/articles/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/", "https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Ba9878186-08f0-440f-8cda-5711331892f1%7D/novel-anti-vegf-for-wet-amd-meets-safety-tolerability-endpoint", "/salud-ocular/enfermedades/drusas", "/salud-ocular/enfermedades/dmre-simulador", "/salud-ocular/enfermedades/vitaminas-para-dmre", "https://www.aao.org/eye-health/ask-ophthalmologist-q/with-dry-amd-is-there-risk-geographic-atrophy", "https://eyesight.org/2019/06/08/promising-update-on-apl-2-for-dry-amd/", "https://lowvision.preventblindness.org/2019/10/29/zimura-for-dry-amd-continues-to-show-positive-results-in-trials/", "https://www.apellis.com/our-science/", "/salud-ocular/consejos/terapia-de-ceulas-madre-para-enfermedad-ocular", "https://www.aao.org/salud-ocular/consejos-lista", "/salud-ocular/consejos/agudeza-visual", "/salud-ocular/consejos/agudeza-visual", "/biography/bcd5e286-e146-4106-97dd-dff47a008c47", "/salud-ocular/consejos/informaci%c3%b3n-sobre-salud-ocular-para-adultos-mayore", "/salud-ocular/consejos/informaci%c3%b3n-sobre-salud-ocular-para-adultos-mayore", "/biography/eac93724-3619-4834-8f38-50520c476300", "/salud-ocular/consejos/informaci%c3%b3n-para-la-salud-ocular-en-adultos-menore", "/salud-ocular/consejos/informaci%c3%b3n-para-la-salud-ocular-en-adultos-menore", "/biography/eac93724-3619-4834-8f38-50520c476300", "/salud-ocular/consejos/informaci%c3%b3n-de-salud-ocular-para-adultos-de-40-65-", "/salud-ocular/consejos/informaci%c3%b3n-de-salud-ocular-para-adultos-de-40-65-", "/biography/eac93724-3619-4834-8f38-50520c476300", "/salud-ocular/consejos/enfermedades-y-afecciones-oculares-de-la-ninez", "/salud-ocular/consejos/enfermedades-y-afecciones-oculares-de-la-ninez", "/biography/272fced2-36d7-470a-b14a-0dcb2cee253b", "https://secure.aao.org/aao/encontrar-oftalmologo", "/contact", "/about", "/jobs", "/about/financial-relationships", "/salud-ocular/terminos-de-servicio#med", "/salud-ocular/politica-de-privacidad", "/salud-ocular/terminos-de-servicio", "/statement-on-artificial-intelligence", "/help", "/advertising-policies", "/newsroom", "https://ophthjobs.aao.org/", "http://eyewiki.aao.org", "https://www.isrs.org", "http://www.facebook.com/American-Academy-of-Ophthalmology", "http://twitter.com/aao_ophth", "http://www.linkedin.com/company/american-academy-of-ophthalmology", "/youtube-pro", "https://www.facebook.com/AcademyEyeSmart/", "https://twitter.com/AcademyEyeSmart", "https://www.instagram.com/aaoeye/", "/youtube-public", "https://www.facebook.com/Truhlsen-Marmor-Museum-of-Eye-106294080874158/", "https://twitter.com/museumoftheeye", "https://www.instagram.com/museumoftheeye/", "https://www.tripadvisor.com/Attraction_Review-g60713-d9715178-Reviews-Truhlsen_Marmor_Museum_of_the_Eye-San_Francisco_California.html", "https://www.yelp.com/biz/museum-of-the-eye-san-francisco"]}